You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3602 results
  1. VoiceLove: An App-Based COMmunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent/Family SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)

    SBC: VOICELOVE LLC            Topic: N/A

    ICU delirium is a devastating complication of illness, acute trauma, and surgery often resulting in prolonged mechanical ventilation, longer lengths of stay, and long-term disability. Delirium is associated with over 12 times increased odds of developing Alzheimer’s disease (AD) and AD-related dementias (ADRD). In addition, delirium accelerates cognitive decline in AD/ADRD patients. Likewise, pa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome

    SBC: CMTX BIOTECH, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of sepsis patients at risk of acute respiratory distress syndrome (ARDS). According to the U.S. Centers for Disease Control (CDC), at least 1.7 million American adults develop sepsis annually, re ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

    SBC: ARCASCOPE INC.            Topic: NHLBI

    ABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.

    SBC: SPACERX LLC            Topic: NIDA

    ABSTRACT Developing drugs that target the central nervous system (CNS) is hampered by an inability to perform direct in vivo preclinical measurements. Here, we propose to identify an optimal smoking cessation drug candidate by monitoring how our newly synthesized prodrugs alter real-time brain dopamine responses to nicotine. Varenicline (CHANTIX®) is the leading FDA-approved oral medication for s ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Designing and validating optimal nonaddictive analgesics using the CANDO paradigm

    SBC: MEDITATI INC            Topic: NIDA

    ABSTRACT We propose a novel holistic paradigm to help solve the opioid crisis by using proteome scale deep learning approaches to design optimal nonaddictive analgesics. We will design compounds that target specific proteins and pathways the combine the pain relieving effects of long acting drugs such as methadone and buprenorphine while modulating additional interactions to ensure optimal pharma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Digital clinical hypnosis for chronic pain management

    SBC: HYPNOSCIENTIFIC, INC.            Topic: R

    Project Summary Chronic pain is a prevalent, disabling problem affecting as many as 116 million adults in the United States. However, there are very few treatment options for chronic pain management, and those that are available are inadequate for the majority of those with this condition. Many also have significant negative side effects or are associated with significant adverse events. A growing ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia

    SBC: CMTX BIOTECH, INC.            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to commercialize a proprietary, clinical-stage, small- molecule drug candidate for the prevention of respiratory distress syndrome (RDS) and its long-term sequelae, bronchopulmonary dysplasia (BPD), in preterm infants. BPD is a chronic respiratory disease that occurs in preterm infants who develop RDS from a combination of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility and design of a novel smartphone app to deliver blood pressure-lowering inspiratory muscle strength training

    SBC: KLEIN BUENDEL, INC.            Topic: NHLBI

    PROJECT SUMMARYHigh blood pressure (BP), particularly high systolic BP (SBP), is the major modifiable risk factor for cardiovascular diseases (CVD) and related conditions. Indeed, over 50% of all adults have above-normal SBP (≥120 mmHg), placing them at increased disease risk. In addition, these adults face ~$2000/year in excess medical expenses compared to their peers with normal BP. Rates of B ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government